View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, May 27 (HealthDay News) -- Baxter International Inc. has announced a voluntary recall of hyaluronidase human injection (Hylenex recombinant), as particulate matter was found in a limited number of vials during standard stability testing.
Hyaluronidase human injection is a tissue permeability modifier used to increase the dispersion and absorption of other injected drugs and to improve resorption of radiopaque agents, as well as for achieving hydration in administration of subcutaneous fluid. The voluntary recall was issued as a precautionary measure because some vials of the drug were found to contain small glass particles.
To date, no adverse events linked to this issue have been reported. Approximately 3,500 vials of the drug are estimated to be in the marketplace, and the company is contacting customers to request the drug be returned to the company. The root cause of the issue has yet to be determined.
"Baxter is working with the product's new drug application-holder, Halozyme Therapeutics, to investigate the root cause of the issue and appropriately address the situation," according to the FDA's safety alert.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top